ReGen CEO criticizes decision to rescind knee implant's clearance

10/19/2010 | Wall Street Journal, The

The FDA's plan to nullify the 510(k) clearance of ReGen Biologics' Menaflex knee implant was "totally unbelievable" and is being driven by a "political agenda," according to ReGen CEO Gerald Bisbee. Dr. Jeffrey Shuren, head of the FDA's device unit, countered the company's statement, saying the agency thoroughly reviewed the process for clearing the device and has the power to revoke the approval.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA